Rival BTK degraders face off in CLL patients naive to BTK inhibition.
ApexOnco Front Page
Recent articles
Talvey looks good with Darzalex in the second line, while Pomalyst’s role is less clear.
AstraZeneca and Lilly put PARP1 and KRAS G12C inhibitors into their first phase 3s, while Amgen advances DLL3 into early-stage disease.
Ikena is savaged in a bear market after reporting zero remissions in a dose-escalation trial of its lead asset.
Akeso’s cadonilimab hits in its first-line study, but there’s no US data and no US partner.
Keymed’s AstraZeneca-partnered anti-Claudin18.2 ADC looks better than Astellas’s zolbetuximab – albeit on an extremely unreliable metric.
A domvanalimab triplet shows some promise in high PD-L1-expressing gastric cancer patients, but caveats abound.
A 14% ORR with IDRX-42 in fourth-line GIST looks better than the 9% previously seen with Qinlock.